CCB Safety Study in Treatment of Hypertension of ADPKD
Status:
Unknown status
Trial end date:
2012-11-01
Target enrollment:
Participant gender:
Summary
This study examines the safety and efficacy of calcium channel blocker (CCB) in the treatment
of hypertension of Autosomal Dominant Polycystic Kidney Disease (ADPKD) patients. Angiotensin
receptor blocker (ARB) was shown to have kidney protecting effects in patients with renal
diseases including ADPKD, glomerulonephritis and diabetic nephropathy. In case whose blood
pressure is not normalized by ARB alone, CCB is selected additionally. Recent research
suggests genetic calcium channel disorder is responsible for the progression of ADPKD. It is
not examined clinically if CCB treatment has any harmful effect to patients with ADPKD. This
study examines the safety of Cilnidipine (CCB) in the ADPKD patients whose blood pressure is
not controlled under 130/85 mmHg by Candesartan (ARB) alone.